Towards comprehensive characterization of HER2 overexpression.
Berezov
Alan
A
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, PA, USA.
Greene
Mark I
MI
D001940:Breast / Q000166:cytology*; D002455:Cell Division / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D002460:Cell Line / Q000187:drug effects / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D066246:ErbB Receptors / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D005260:Female; D015870:Gene Expression; D018773:Genes, erbB-1; D018734:Genes, erbB-2; D006801:Humans; D013058:Mass Spectrometry; D020890:Neuregulin-1 / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D019000:Phosphotyrosine / Q000502:physiology*; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000737:chemistry / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects
D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D020890:Neuregulin-1; D019000:Phosphotyrosine; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins